Bridge Lab Biotech builds transparent, assumption-driven valuation models for U.S.-listed biotech companies. Each model forecasts pipeline sales bottom-up — addressable patients, on-therapy rate, penetration, net price, risk-adjusted by probability of success — rolls the parts up into a per-share price target, and lets you change any assumption live in the browser.
Every number is an order-of-magnitude estimate for research and discussion. Nothing here is investment advice.
What each model covers:
Individual models are shared privately by direct link.
This page intentionally lists none.
© Bridge Lab Biotech